A Non-Invasive CNS Drug Transporter
ExQor's business centers on a unique transporter platform that enables and enhances drug delivery to the central nervous system, fulfilling critical needs in product portfolios of the pharmaceutical and biotech industries, such as:
- Enabling non-invasive transport of large molecule drugs past an intact blood brain barrier to more effectively treat CNS diseases and disorders such as CNS cancers, neurodegenerative diseases, autoimmune CNS diseases, genetic defects, psychiatric illnesses, and others.
- Enhancing diagnostic agent capabilities for early detection of diseases like Alzheimer's and Parkinson's.
- Enabling more effective therapeutic intervention for improved CNS treatment outcomes, and while using much lower drug doses.
- Enhancing patient compliance because of decreased drug side effects.
Large, and small, molecule drug payloads of most any type can be precisely targeted by the multi-patented ExQor transporter to the brain, which uses a non-antigenic, non-toxic, non-immunogenic self-assembling protein.